About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

XARACOLL

Latest News

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

31 Aug
XARACOLL is a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCl directly to the surgical site providing long-lasting pain...
Read More

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain

26 Mar
- FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of August 26, 2020- ATHLONE, Ireland, March 26, 2020...
Read More

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

27 Feb
ATHLONE, Ireland, Feb. 27, 2020 /PRNewswire/ -- Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited